- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00672139
Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness
Open-Label Extension Study To Assess The Safety Of A Fixed Dose Of Subcutaneous Methylnaltrexone In Subjects With Advanced Illness And Opioid-Induced Constipation
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
-
Adelaide, Australien, 5000
- Salix Investigational Site
-
-
Victoria
-
Coburg, Victoria, Australien, 3058
- Salix Investigational Site
-
East Melbourne, Victoria, Australien, 3002
- Salix Investigational Site
-
-
-
-
-
Leuven, Belgien, B-3000
- Salix Investigational Site
-
-
-
-
-
Quebec, Canada, G1R 3S1
- Salix Investigational Site
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Salix Investigational Site
-
Edmonton, Alberta, Canada, T6L 5X8
- Salix Investigational Site
-
-
Ontario
-
Hamilton, Ontario, Canada, L8M 1W9
- Salix Investigational Site
-
London, Ontario, Canada, N6A 4L6
- Salix Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canada, H3A 1A1
- Salix Investigational Site
-
-
-
-
Gloucestershire
-
Cheltenham, Gloucestershire, Det Forenede Kongerige, GL53 0Qj
- Salix Investigational Site
-
-
-
-
Alabama
-
Mobile, Alabama, Forenede Stater, 36604
- Salix Investigational Site
-
-
California
-
Laguna Hills, California, Forenede Stater, 92637
- Salix Investigational Site
-
Lancaster, California, Forenede Stater, 93534
- Salix Investigational Site
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Salix Investigational Site
-
-
Florida
-
Auburndale, Florida, Forenede Stater, 33823
- Salix Investigational Site
-
Hudson, Florida, Forenede Stater, 34667
- Salix Investigational Site
-
Lakeland, Florida, Forenede Stater, 33805
- Salix Investigational Site
-
Lakeland, Florida, Forenede Stater, 33815
- Salix Investigational Site
-
Miami Springs, Florida, Forenede Stater, 33166
- Salix Investigational Site
-
Ruskin, Florida, Forenede Stater, 33573
- Salix Investigational Site
-
Sebring, Florida, Forenede Stater, 33870
- Salix Investigational Site
-
Tampa, Florida, Forenede Stater, 33609
- Salix Investigational Site
-
Tampa, Florida, Forenede Stater, 33612-9416
- Salix Investigational Site
-
Tampa, Florida, Forenede Stater, 33619
- Salix Investigational Site
-
Temple Terrace, Florida, Forenede Stater, 33617
- Salix Investigational Site
-
-
New Jersey
-
Orange, New Jersey, Forenede Stater, 07018
- Salix Investigational Site
-
-
North Carolina
-
Flat Rock, North Carolina, Forenede Stater, 28731
- Salix Investigational Site
-
Winston-Salem, North Carolina, Forenede Stater, 27103-5766
- Salix Investigational Site
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44119
- Salix Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19111
- Salix Investigational Site
-
-
Texas
-
Austin, Texas, Forenede Stater, 78757
- Salix Investigational Site
-
Houston, Texas, Forenede Stater, 77030
- Salix Investigational Site
-
-
Utah
-
American Fork, Utah, Forenede Stater, 84003
- Salix Investigational Site
-
Orem, Utah, Forenede Stater, 84058
- Salix Investigational Site
-
Provo, Utah, Forenede Stater, 84604
- Salix Investigational Site
-
-
Wisconsin
-
Madison, Wisconsin, Forenede Stater, 53792
- Salix Investigational Site
-
-
-
-
-
Montpellier, Frankrig, 34295
- Salix Investigational Site
-
-
-
-
-
L'Aquila, Italien, 67100
- Salix Investigational Site
-
Milan, Italien, 20020
- Salix Investigational Site
-
Milano, Italien, 20133
- Salix Investigational Site
-
Roma, Italien, 00144
- Salix Investigational Site
-
-
-
-
-
Mexico City DF, Mexico, 03600
- Pfizer Investigational Site
-
-
-
-
-
Almada, Portugal, 2801-951
- Salix Investigational Site
-
Porto, Portugal, 4200-072
- Salix Investigational Site
-
-
-
-
-
Berlin, Tyskland, 14089
- Salix Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Has completed study 3200K1-4000-WW, including 2 weeks of therapy and completion of all post baseline efficacy, safety, and health outcomes assessments.
- Is receiving opioids on a regular schedule, not just as needed to control pain.
- Likely to continue to need treatment of OIC for the duration of participation in the study.
Exclusion Criteria:
- Has a suspected mechanical gastrointestinal obstruction, fecal impaction, or clinically important active diverticular disease as determined by the investigator.
- Currently using an opioid antagonist or partial antagonist.
- Has any other clinically important abnormalities such that risk to patient of participation outweighs the potential benefit of therapy as determined by the investigator
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Methylnaltrexone bromide
Methylnaltrexone subcutaneously as needed no more than 1 dose in a 24-hour period for a maximum of 10 weeks in this study. Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; or 0.4 mL (8 mg) every other day if weight between 38 and <62 kg. Subjects with impaired kidney function received reduced doses according to instructions in the Relistor prescribing information. |
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Number of Laxations Per Subject Within 24 Hours of Dosing Per Week.
Tidsramme: 10 weeks
|
This was defined as the total number of days with a laxation (ie, a bowel movement) within 24 hours after dosing in each 7-day interval after the start of dosing.
Results shown are the ranges (lowest and highest weekly values) of mean (± standard deviation) numbers of laxations within 24 hours of dosing per week during the 10-week treatment period for each group.
|
10 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Studieleder: Enoch Bortey, Bausch Health Americas, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Psykiske lidelser
- Kemisk inducerede lidelser
- Stof-relaterede lidelser
- Tegn og symptomer, fordøjelsessystemet
- Narkotika-relaterede lidelser
- Forstoppelse
- Opioid-induceret obstipation
- Lægemidlers fysiologiske virkninger
- Agenter fra det perifere nervesystem
- Sensoriske systemagenter
- Narkotiske antagonister
- Antikonvulsiva
- Bromider
- Methylnaltrexon
Andre undersøgelses-id-numre
- 3200K1-4001
- B2541006
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Opioid-induceret obstipation
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development... og andre samarbejdspartnereAfsluttetHemiplegi | Spædbørns udvikling | Constraint Induced Movement TherapyForenede Stater
-
University of SevilleAfsluttetFamilie | Infantil Hemiplegi | Constraint Induced Movement Therapy | Bimanuel intensiv terapiSpanien
-
Fondation LenvalRekrutteringFood Protein Induced Enterocolitis Syndrome (FPIES)Frankrig
-
University of MichiganThe Benter FoundationAktiv, ikke rekrutterendeOpioid ordinationForenede Stater
-
matthieu clanetAfsluttet
-
University of MichiganNational Institute on Drug Abuse (NIDA)AfsluttetOpioid ordinationForenede Stater
-
University of North Carolina, Chapel HillNorth Carolina Department of Health and Human ServicesAfsluttetAnalgetika OpioidForenede Stater
-
Purdue Pharma LPAfsluttetOpioid analgesiForenede Stater, Australien, Finland, New Zealand
-
CEU San Pablo UniversityUkendtParese i øvre ekstremitet | Familie | Infantil Hemiplegi | Constraint Induced Movement Therapy | Bimanuel intensiv terapiSpanien
-
Second Hospital of Shanxi Medical UniversityRekrutteringOpioid analgetisk bivirkningKina
Kliniske forsøg med Methylnaltrexone bromide
-
Samsung Medical CenterRekrutteringKronisk obstruktiv lungesygdom | Ikke småcellet lungekræftKorea, Republikken
-
Bausch Health Americas, Inc.AfsluttetSunde emnerForenede Stater
-
Bausch Health Americas, Inc.Afsluttet
-
Bausch Health Americas, Inc.AfsluttetSunde frivilligeForenede Stater
-
Bausch Health Americas, Inc.AfsluttetSunde voksneForenede Stater
-
Bausch Health Americas, Inc.AfsluttetLeverdysfunktionForenede Stater
-
Bausch Health Americas, Inc.Afsluttet
-
Botanix PharmaceuticalsAfsluttetPrimær aksillær hyperhidroseForenede Stater
-
Bausch Health Americas, Inc.AfsluttetNedsat nyrefunktionForenede Stater
-
Bausch Health Americas, Inc.Wyeth is now a wholly owned subsidiary of PfizerAfsluttetAdvance sygdom patienter med OICForenede Stater